Brief: Star Combo Pharma Says Qtrly Group Revenue Was A$5.0 Mln
May 3 (Reuters) - Star Combo Pharma Ltd S66.AX :
* S66 BUSINESS UPDATE Q3
* RETAIL DIVISION OF STAR COMBO CONTINUED TO BE IMPACTED BY
COVID
PANDEMIC AS DECREASED TOURISM CONTINUED
* QTRLY GROUP REVENUE WAS A$5.0M VERSUS A$6.1M
* FY22 OUTLOOK POSITIVE FOR CORE OEM BUSINESS
* WILL CONTINUE TO BE CONSTRAINED BY SUPPLY CHALLENGES
* EXPECT INCREASE IN OUTPUT IN 1H2023
Source text for Eikon: ID:nASX8gvVM2
Further company coverage: S66.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Star Combo Pharma
See all newsBrief: Star Combo Pharma Announces Insurance Claim Settlement Of A$5 Million
Brief: Star Combo Pharma Says Outlook For FY2025 Is Positive
Brief: Star Combo Pharma Says HY Operating Loss Attributable A$4.4 Million
Brief: Star Combo Pharma Posts Q1 Fy23 Revenue Of A$6.55M
Australia's Star Combo Pharma plunges to record low on fire incident